NRX Pharmaceuticals, Inc. 2025 Annual Report: Key Investor Insights

NRX Pharmaceuticals, Inc. has released its Annual Report for the fiscal year ended December 31, 2025. The report is comprehensive and contains several key points and disclosures relevant for shareholders and investors. Below, we have analyzed and expanded on the most important content, including any price-sensitive information that could affect share values.

1. Company Overview

NRX Pharmaceuticals, Inc. is a Delaware-incorporated pharmaceutical preparations company, trading under the ticker NRXP on Nasdaq. Its business address is 1201 Orange Street, Suite 600, Wilmington, DE 19801, and its telephone number is 484-254-6134.

2. Securities Overview

• Common Stock: Par value \$0.001 per share, listed as NRXP on Nasdaq.
• Warrants to Purchase Common Stock: Listed as NRXPW on Nasdaq.
• No securities registered under Section 12(g) of the Act.
• As of March 23, 2026, there were 33,067,630 shares of common stock outstanding.
• Market Value: The aggregate market value of common stock held by non-affiliates as of June 30, 2025, was \$57.4 million.

3. Regulatory Compliance and Reporting Status

• NRX is not a well-known seasoned issuer and is classified as a non-accelerated filer and a smaller reporting company.
• NRX is not an emerging growth company and not a shell company.
• The company has filed all required reports and submitted all Interactive Data Files in the past 12 months.
• No error corrections or restatements required recovery analysis of incentive-based compensation.

4. Capital Structure and Stock Details

NRX Pharmaceuticals has authorized 500,000,000 shares of common stock and 50,000,000 shares of preferred stock. As of December 31, 2025, 31,734,333 shares of common stock were issued and outstanding. No Series A Convertible Preferred Stock was issued or outstanding at year-end, though 12,000,000 shares were authorized for this series.

5. Price-Sensitive and Shareholder-Relevant Items

• Increase in Common Shares Outstanding: The number of common shares outstanding increased significantly from 14,591,505 at the end of 2024 to 31,734,333 at the end of 2025, and further to 33,067,630 as of March 23, 2026. This substantial dilution could impact share price and investor ownership percentages.
• Cybersecurity Risk Management: The company has established committees responsible for cybersecurity oversight. It reports that no material adverse cybersecurity events occurred in 2025. This is important for investor confidence, as cyber incidents can materially affect operations and share value.
• Debt and Warrants: No debt instruments were outstanding as of December 31, 2025, and no preferred shares were issued or outstanding. There are various warrants to purchase common stock, which represent potential future dilution and could impact share pricing.
• Intangible Assets: NRX reports two reportable and operating segments, with finite-lived intangible assets including customer lists and trade names. Measurement periods for these assets are three to four years, which may affect future amortization and asset values.
• ATM Offerings and Other Stock Issuances: The report references multiple stock offerings, including ATM (At-The-Market) offerings, registered direct offerings, private placements, and consideration shares. These capital-raising activities are likely to affect both liquidity and share price through further dilution.
• No Income Tax Expense: NRX reports zero income tax expense for 2025 and 2024, potentially indicating ongoing net losses or the utilization of net operating loss carryforwards. This has implications for profitability and future tax obligations.
• Legal Proceedings: Legal proceedings are referenced but not detailed in the table of contents. Investors should monitor for updates, as litigation can materially affect financial and share performance.

6. Other Notable Disclosures

• Internal Controls: The company has not filed an auditor attestation report on internal controls over financial reporting, which could be relevant for risk assessment.
• Financial Statements: The annual report includes management discussion and analysis, financial statements, supplementary data, and disclosures about controls, procedures, and market risk. These sections are important for a deeper evaluation of the company’s financial health and risk profile.

7. Potential Share Price Impact

The most price-sensitive factors in this report are:

• Significant dilution of common stock due to capital raises, ATM offerings, and warrant exercises, which may negatively impact share price and investor holdings.
• No material cybersecurity incidents, which is a positive for investor confidence but may not directly impact share price unless future events occur.
• Zero income tax expense, suggesting ongoing losses, which could weigh on valuation and investor sentiment.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full Annual Report and consult with financial professionals before making any investment decisions. The information presented is based on the official SEC filings and may be subject to change or further updates.

View NRX Pharmaceuticals, Inc. Historical chart here